ASX Announcement 17 November 2026 BCAL expands breast cancer biomarker program and advances scientific validation Highlights • Human Research Ethics Committee approval received to expand BCAL’s existing breast cancer sample collection and analysis program to include multiomic assay development....
BCAL Expands Breast Cancer Biomarker Program
Filed with ASX · · 2 pages · English
Summary by 6ix AI
BCAL Diagnostics Limited has announced the expansion of its breast cancer biomarker program and advancements in scientific validation, including receiving ethics approval for multiomic assay development. The company has published a manuscript in a peer-reviewed journal detailing its lipidomics framework for breast cancer diagnostics and submitted another paper currently under revision. These developments enhance BCAL's clinical development pathway and broaden its research capabilities for future diagnostic applications.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
BCAL Diagnostics Limited on 6ix
Earlier from BCAL Diagnostics
- Notification of cessation of securities - BDX
- Application for quotation of securities - BDX
- GSS - Panel Receives Application
- Change of Director's Interest Notice
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from BCAL Diagnostics
All BCAL Diagnostics news releasesFollow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics